{
    "xml": "<topic id=\"PHP34116\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/pomalidomide\" basename=\"pomalidomide\" title=\"POMALIDOMIDE\">\n<title>POMALIDOMIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1273\" namespace=\"/interactions/list-of-drug-interactions/pomalidomide\">Pomalidomide</xref>\n</p>\n<data name=\"vtmid\">703790009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_792531064\" title=\"Thalidomide and related anologues\">Thalidomide and related anologues</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP69898\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/pomalidomide\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<b>Pomalidomide</b> is structurally related to thalidomide and has immunomodulatory properties and direct anti-myeloma tumoricidal activity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69839\" outputclass=\"indicationsAndDose\" rev=\"1.18\" parent=\"/drugs/pomalidomide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>4&#8239;mg once daily for 21 consecutive days of repeated 28&#8211;day cycles, for doses of dexamethasone and dose adjustment due to side effects&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69992\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/pomalidomide\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiac disease</ph>; <ph outputclass=\"caution\">cardiac risk factors</ph>; <ph outputclass=\"caution\">high tumour burden&#8212;risk of tumour lysis syndrome</ph>; <ph outputclass=\"caution\">interstitial lung disease&#8212;discontinue if suspected</ph>; <ph outputclass=\"caution\">peripheral neuropathy</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Thromboembolism</p>\n<p>Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis should be considered, particularly in patients with additional risk factors.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Second primary malignancy</p>\n<p>Patients should be carefully evaluated before and during treatment with pomalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69812\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/pomalidomide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (pomalidomide).</p>\n<p>Use caution with concomitant drugs that increase the risk of bleeding or thromboembolism.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69716\" outputclass=\"sideEffects\" rev=\"1.24\" parent=\"/drugs/pomalidomide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">bone pain</ph>; <ph outputclass=\"sideEffect\">cardiac failure</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">decreased appetite</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">febrile neutropenia</ph>; <ph outputclass=\"sideEffect\">hyperkalaemia</ph>; <ph outputclass=\"sideEffect\">hyponatraemia</ph>; <ph outputclass=\"sideEffect\">impaired consciousness</ph>; <ph outputclass=\"sideEffect\">interstitial lung disease</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">muscle spasms</ph>; <ph outputclass=\"sideEffect\">nasopharyngitis</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">neutropenic sepsis</ph>; <ph outputclass=\"sideEffect\">pelvic pain</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">pneumonia</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">renal failure</ph>; <ph outputclass=\"sideEffect\">respiratory tract infection</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">thromboembolic events</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">urinary retention</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Atrial fibrillation</ph>; <ph outputclass=\"sideEffect\">pulmonary oedema</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69972\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/pomalidomide\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For women of child-bearing potential, pregnancy must be excluded before starting treatment with pomalidomide (perform pregnancy test on initiation or within 3 days prior to initiation).</p>\n<p>Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intrauterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer&#8217;s Pregnancy Prevention Programme.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69790\" outputclass=\"pregnancy\" parent=\"/drugs/pomalidomide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>\n<b>Important: teratogenic risk</b>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69999\" outputclass=\"breastFeeding\" parent=\"/drugs/pomalidomide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69871\" outputclass=\"hepaticImpairment\" parent=\"/drugs/pomalidomide\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69740\" outputclass=\"renalImpairment\" parent=\"/drugs/pomalidomide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69662\" outputclass=\"monitoringRequirements\" parent=\"/drugs/pomalidomide\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor full blood count before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop&#8212;consult product literature).</p>\n<p>Monitor for arterial or venous thromboembolism.</p>\n<p>Monitor for signs and symptoms of cardiac failure.</p>\n<p>Monitor for acute onset or unexplained worsening of respiratory symptoms.</p>\n<p>Monitor liver function for 6 months after initiation, then as clinically indicated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58161\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.9\" parent=\"/drugs/pomalidomide\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69776\" outputclass=\"patientAndCarerAdvice\" rev=\"1.25\" parent=\"/drugs/pomalidomide\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"patientAdviceInConceptionAndContraception\">\n<title>Patient advice required around conception and contraception</title>\n<sectiondiv>\n<p>Patient counselling is advised for pomalidomide capsules (pregnancy and contraception).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69643\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/drugs/pomalidomide\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA338</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (March 2015)</p>\r\n<p>Pomalidomide, in combination with dexamethasone, is <b>not</b> recommended for the treatment of relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA338\">www.nice.org.uk/TA338</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP34116-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pomalidomide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75162\" title=\"Capsule\" namespace=\"/drugs/pomalidomide/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1273\" namespace=\"/interactions/list-of-drug-interactions/pomalidomide\" title=\"Pomalidomide\" count=\"1\" rel=\"link\">Pomalidomide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75162\" namespace=\"/drugs/pomalidomide/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP34116",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/pomalidomide",
    "basename": "pomalidomide",
    "title": "POMALIDOMIDE",
    "interactants": [
        {
            "id": "bnf_int_1273",
            "label": "Pomalidomide"
        }
    ],
    "vtmid": "703790009",
    "drugClassification": [
        "Thalidomide and related anologues"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Pomalidomide is structurally related to thalidomide and has immunomodulatory properties and direct anti-myeloma tumoricidal activity.",
                "html": "<p>\n<b>Pomalidomide</b> is structurally related to thalidomide and has immunomodulatory properties and direct anti-myeloma tumoricidal activity.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)",
                        "html": "Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "4 mg once daily for 21 consecutive days of repeated 28&#8211;day cycles, for doses of dexamethasone and dose adjustment due to side effects&#8212;consult product literature.",
                        "html": "<p>4&#8239;mg once daily for 21 consecutive days of repeated 28&#8211;day cycles, for doses of dexamethasone and dose adjustment due to side effects&#8212;consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiac disease",
                "html": "Cardiac disease"
            },
            {
                "type": "cautions",
                "textContent": "cardiac risk factors",
                "html": "cardiac risk factors"
            },
            {
                "type": "cautions",
                "textContent": "high tumour burden&#8212;risk of tumour lysis syndrome",
                "html": "high tumour burden&#8212;risk of tumour lysis syndrome"
            },
            {
                "type": "cautions",
                "textContent": "interstitial lung disease&#8212;discontinue if suspected",
                "html": "interstitial lung disease&#8212;discontinue if suspected"
            },
            {
                "type": "cautions",
                "textContent": "peripheral neuropathy",
                "html": "peripheral neuropathy"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Thromboembolism",
                "textContent": "Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis should be considered, particularly in patients with additional risk factors.",
                "html": "<p>Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis should be considered, particularly in patients with additional risk factors.</p>"
            },
            {
                "type": "importantAdvice",
                "title": "Second primary malignancy",
                "textContent": "Patients should be carefully evaluated before and during treatment with pomalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.",
                "html": "<p>Patients should be carefully evaluated before and during treatment with pomalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (pomalidomide).\n\nUse caution with concomitant drugs that increase the risk of bleeding or thromboembolism.",
                "html": "<p>Appendix 1 (pomalidomide).</p><p>Use caution with concomitant drugs that increase the risk of bleeding or thromboembolism.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bone pain",
                        "html": "bone pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cardiac failure",
                        "html": "cardiac failure",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "decreased appetite",
                        "html": "decreased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "febrile neutropenia",
                        "html": "febrile neutropenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperkalaemia",
                        "html": "hyperkalaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyponatraemia",
                        "html": "hyponatraemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "impaired consciousness",
                        "html": "impaired consciousness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "interstitial lung disease",
                        "html": "interstitial lung disease",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscle spasms",
                        "html": "muscle spasms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nasopharyngitis",
                        "html": "nasopharyngitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "neutropenic sepsis",
                        "html": "neutropenic sepsis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pelvic pain",
                        "html": "pelvic pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pneumonia",
                        "html": "pneumonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "renal failure",
                        "html": "renal failure",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "respiratory tract infection",
                        "html": "respiratory tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thromboembolic events",
                        "html": "thromboembolic events",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary retention",
                        "html": "urinary retention",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Hepatitis",
                        "html": "Hepatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Atrial fibrillation",
                        "html": "Atrial fibrillation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary oedema",
                        "html": "pulmonary oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For women of child-bearing potential, pregnancy must be excluded before starting treatment with pomalidomide (perform pregnancy test on initiation or within 3 days prior to initiation).\n\nWomen must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intrauterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer&#8217;s Pregnancy Prevention Programme.",
                "html": "<p>For women of child-bearing potential, pregnancy must be excluded before starting treatment with pomalidomide (perform pregnancy test on initiation or within 3 days prior to initiation).</p><p>Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intrauterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer&#8217;s Pregnancy Prevention Programme.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Important: teratogenic risk.",
                "html": "<p>\n<b>Important: teratogenic risk</b>.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop&#8212;consult product literature).\n\nMonitor for arterial or venous thromboembolism.\n\nMonitor for signs and symptoms of cardiac failure.\n\nMonitor for acute onset or unexplained worsening of respiratory symptoms.\n\nMonitor liver function for 6 months after initiation, then as clinically indicated.",
                "html": "<p>Monitor full blood count before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop&#8212;consult product literature).</p><p>Monitor for arterial or venous thromboembolism.</p><p>Monitor for signs and symptoms of cardiac failure.</p><p>Monitor for acute onset or unexplained worsening of respiratory symptoms.</p><p>Monitor liver function for 6 months after initiation, then as clinically indicated.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.",
                "html": "<p>Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.",
                "html": "<p>Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.",
                "html": "<p>Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.</p>"
            }
        ],
        "patientAdviceInConceptionAndContraception": [
            {
                "type": "patientAdviceInConceptionAndContraception",
                "textContent": "Patient counselling is advised for pomalidomide capsules (pregnancy and contraception).",
                "html": "<p>Patient counselling is advised for pomalidomide capsules (pregnancy and contraception).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA338",
                        "label": "www.nice.org.uk/TA338"
                    }
                ],
                "fundingIdentifier": "NICE TA338",
                "textContent": "Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (March 2015) Pomalidomide, in combination with dexamethasone, is not recommended for the treatment of relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy.\n\nwww.nice.org.uk/TA338",
                "html": "<p outputclass=\"title\">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (March 2015)</p> <p>Pomalidomide, in combination with dexamethasone, is <b>not</b> recommended for the treatment of relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA338\">www.nice.org.uk/TA338</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75162",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1273",
                "label": "Pomalidomide",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75162",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}